following an abbreviated submission:
mepolizumab (Nucala®) is accepted for restricted use within NHSScotland.
Indication under review: as an add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older.
SMC restriction: patients who have eosinophils of at least 150 cells per microlitre (0.15 x 109/L) at initiation of treatment and have had at least four asthma exacerbations in the preceding year or are receiving maintenance treatment with oral corticosteroids.
SMC has previously accepted mepolizumab for restricted use in adults.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of mepolizumab. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
Download detailed advice367KB (PDF)
- Medicine name:
- mepolizumab (Nucala)
- SMC ID:
- Add-on therapy for children (6y+), adolescents, and adults with severe refractory eosinophilic asthma
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Respiratory system
- Submission type
- Date advice published
- 08 April 2019